Evidence map›Paper›PMID 38722235›Full record

ArticleFuture medicinal chemistry2024

Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.

Noha Ryad, Ayman Abo Elmaaty, Ibrahim M Ibrahim, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Rasha Mohammed Saleem, Islam Zaki, Lina M A Abdel Ghany

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noha RyadPharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences & Drug Manufacturing, Misr University for Science & Technology, 6th of October City, Giza, Egypt.
Ayman Abo ElmaatyMedicinal Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, 42526, Egypt.
Ibrahim M IbrahimDepartment of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Ali Hassan Ahmed MaghrabiDepartment of Biology, Faculty of Applied Science, Umm Al-Qura University, Makkah, 24381, Saudi Arabia.
Maryam Abdulrahman Yahya AlahdalDepartment of Biology, Faculty of Applied Science, Umm Al-Qura University, Makkah, 24381, Saudi Arabia.
Rasha Mohammed SaleemDepartment of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha, 65431, Saudi Arabia.
Islam ZakiPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said,  42526, Egypt.ORCID 0000-0002-2026-7373
Lina M A Abdel GhanyPharmaceutical Chemistry Department, College of Pharmaceutical Sciences & Drug Manufacturing, Misr University for Science & Technology, 6th of October City, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsProtein Kinase InhibitorsQuinolinesCell Line, TumorDose-Response Relationship, DrugDrug DiscoveryHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsquinolineQuinolinesADMETanti-proliferativeEGFRmolecular dockingmolecular hybridizationquinolineSAR

Identifiers

PMID38722235
PMCPMC11216632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.